A
Alcista
Alcista · 25%MAZE
$21.54
Precio del escenario
$32.580
+0.130 (+0.40%)Al cierre
Loading chart…
- Máximo
- 33.185
- Apertura
- 32.520
- Precio medio ponderado por volumen
- 32.44
- Volumen
- 1.07M
- Capitalización
- —
- Mínimo
- 31.555
- Importe
- 34.66M
- EV/EBITDA, TTM
- -31.57
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Análisis de IA of Maze Therapeutics Inc (MAZE)
ComprarMaze Therapeutics is a good buy right now, as it is currently priced at $27.53, with a forward P/E of 8.53, indicating potential undervaluation. The RSI is at 61.38, suggesting bullish momentum, and analysts project significant upside with targets of $50 and $64. However, the main risk is the recent insider stock sale by the Chief Medical Officer, which may indicate concerns about the company's future prospects.
Métricas de valoración
El PER previsto actual de Maze Therapeutics Inc (MAZE) es 8.53, frente a su media de 5 años de 1.46.
Escenarios de precio de Alphio AI para MAZE
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con MAZE en cartera
Cronología de eventos
Noticias
Preguntas frecuentes sobre MAZE, respondidas por Alphio AI
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target. It operates in the Healthcare sector.
Maze Therapeutics is a good buy right now, as it is currently priced at $27.53, with a forward P/E of 8.53, indicating potential undervaluation. The RSI is at 61.38, suggesting bullish momentum, and analysts project significant upside with targets of $50 and $64. However, the main risk is the recent insider stock sale by the Chief Medical Officer, which may indicate concerns about the company's future prospects.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.